Clinical trial
Erlotinib in Treating Patients With Persistent or Recurrent Cancer of the Cervix
NCT00031993 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00031993 |
|---|---|
| Title | Erlotinib in Treating Patients With Persistent or Recurrent Cancer of the Cervix |
| Official title | A Phase II Evaluation Of OSI-774 (NSC #718781) In The Treatment Of Persistent or Recurrent Squamous Cell Carcinoma Of The Cervix |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cervical Squamous Cell Carcinoma, Recurrent Cervical Cancer |
| Intervention type | Drug, Other |
| Interventions | erlotinib hydrochloride, laboratory biomarker analysis |
| Enrollment | 51 |
| Start date | Mar 1, 2002 |
| Primary completion | Nov 1, 2005 |
| First posted | Jan 27, 2003 |
| Last update posted | Jan 17, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: